Bhavana Pathak, MD
Hematology & Oncology · Orange, CANPI 1154610319
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $631 of the $731 with a category attached, or 86.3%. It is spread thinly across 13 manufacturers, the largest accounting for just 21.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $289 and has fallen 91.5% since, to $24 in 2025. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 22 payments — averaging $33.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$158
- Janssen Scientific Affairs, LLC$141
- Pharmacyclics LLC, An Abbvie Company$122
- Novartis$66
- Puma Biotechnology, Inc.$64
- Gilead$38
- plus $142 from 7 others
What the payments were for
- Food & beverage$63186%
- Education$10014%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 4 | $158 |
| Janssen Scientific Affairs, LLC | 2 | $141 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $122 |
| Novartis | 3 | $66 |
| Puma Biotechnology, Inc. | 3 | $64 |
| Gilead | 2 | $38 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Amgen | 1 | $23 |
| Incyte Corporation | 1 | $21 |
| Mylan Institutional Inc. | 1 | $20 |
| Sanofi | 1 | $19 |
| Pfizer | 1 | $18 |
| Seagen Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$731 in reported general payments places this provider in the 25th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamoxifen Citrate | 180 | $2,988 |
| Fulvestrant | 12 | $2,578 |
| Exemestane | 22 | $2,338 |
| Anastrozole | 153 | $2,146 |
| Raloxifene Hcl | 13 | $698 |
| Letrozole | 25 | $412 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Orange
- Catherine CoombsOrange$786K
- Arash Rezazadeh KalebastyOrange$516K
- Misako NagasakaOrange$507K
- Elizabeth BremOrange$335K
- May ChoOrange$334K
- Angela FleischmanOrange$255K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.